PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40633873,"Discovery of potential RAF selective back pocket as a promising biological site for BRAF inhibitors targeting resistant melanoma opens the door for a new generation of kinase inhibitors: Design, synthesis, biological evaluation, and in silico molecular simulation.",Jul 2025,Jun; Deug,"CTCBIO Inc., Gyeonggi-do 18576, Republic of Korea.; CTCBIO Inc., Gyeonggi-do 18576, Republic of Korea.",
40633540,A Rac-specific competitive inhibitor of guanine nucleotide binding reduces metastasis in triple-negative breast cancer.,Jun 2025,Ferrandez; Cherfils; Sauzeau,"Laboratory of biology and applied pharmacology, CNRS, ENS Paris-Saclay, Paris, France.; Laboratory of biology and applied pharmacology, CNRS, ENS Paris-Saclay, Paris, France.; Nantes Universit√©, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes F-44000, France. Electronic address: vincent.sauzeau@univ-nantes.fr.",vincent.sauzeau@univ-nantes.fr.
40624840,"Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.",Dec 2025,Brennan; Polli; Sathish; Peters; Ji; Witcher; Wang; Doyle; Sharda; Struthers; Stefanich; Honda; Humphreys,"Discovery Research, UCB Pharma, Slough, UK.; Pharmacokinetic Sciences, Translational Medicine, Novartis Biomedical Research, Cambridge, MA, USA.; Comparative Medicine and Drug Safety R&D, Pfizer, Pearl River, NY, USA.; Discovery Research, UCB Pharma, Slough, UK.; Comparative Medicine and Drug Safety R&D, Pfizer, La Jolla, CA, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Amgen Research, Amgen Inc, South San Francisco, CA, USA.; Bristol-Myers Squibb, Princeton, NJ, USA.; Bristol-Myers Squibb, Princeton, NJ, USA.; Bristol-Myers Squibb, Princeton, NJ, USA.; Translational Pharmacokinetics and Pharmacodynamics, Genentech Inc, South San Francisco, CA, USA.; Chugai Pharmaceutical Co., Ltd, Kanagawa, Japan.; Discovery Research, UCB Pharma, Slough, UK.",
40618036,Fasting builds a favorable environment for effective gut microbiota modulation by microbiota-accessible carbohydrates.,Jul 2025,Nakashima,"The Research and Development Department, Euglena Co., Ltd, Tokyo, 108-0014, Japan.",
40607730,"Discovery of TNI-97 as a Highly Selective, Orally Bioavailable HDAC6 Inhibitor for the Treatment of Triple-Negative Breast Cancer.",Jul 2025,Bai,"Qingdao Seawit Life Science Co., Ltd., Qingdao 226221, China.",
